DiaMedica Therapeutics (DMAC) Share-based Compensation (2017 - 2026)

DiaMedica Therapeutics (DMAC) has reported Share-based Compensation for 10 consecutive years, with $8.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 22.36% year-over-year to $8.2 million; the trailing twelve-month figure through Jun 2026 stood at $8.2 million (up 22.36% YoY), and the FY2025 full-year result was $10.6 million, up 125.9% from the prior year.
• Share-based Compensation climbed to $8.2 million in Q2 2026 per DMAC's latest filing, from $6.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $8.2 million in Q2 2026 and bottomed at $411000.0 in Q4 2022.
• Historically, Share-based Compensation has averaged $3.8 million across 5 years, with a median of $3.7 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation rose 10.95% in 2023, then jumped 102.38% in 2025.
• Over 5 years, Share-based Compensation stood at $411000.0 in 2022, then rose by 10.95% to $456000.0 in 2023, then gained by 29.17% to $589000.0 in 2024, then surged by 102.38% to $1.2 million in 2025, then surged by 586.28% to $8.2 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $8.2 million, $6.4 million, and $1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.